Short answer
Maze Therapeutics, Inc. (MAZE) filed its fiscal 2024 10-K annual report with the SEC on Mar 31, 2025. It reported revenue of $168M and net income of $52M.
- Top risk flagged: No geopolitical or macroeconomic threat detailed in the section
FY2024 key financial metrics · XBRL
- Revenue
- $168M
- Net income
- $52M
- Operating margin
- 34.4%
- EPS (diluted)
- $1.25
- ROE
- -16.8%
- Operating cash flow
- $76M
Source: XBRL data from the Maze Therapeutics, Inc. (MAZE) FY2024 10-K on SEC EDGAR. USD.
Maze Therapeutics, Inc. FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Genetic medicine focused on novel drug discovery for complex diseases
- No new products, services, or segments introduced or emphasized in FY 2025 filing
- Continued emphasis on leadership with multiple new director appointments by March 31, 2025
- Executive leadership consolidation: CEO Jason Coloma also acting as Principal Financial Officer
- Filing lacks a formal business summary section, deviating from typical 10-K disclosures
Management Discussion & Analysis
- Revenue $167.5M in 2024 vs $0 in 2023 from license agreements with Shionogi, Trace, Neurocrine
- Net income $52.2M in 2024 vs net loss $100.4M in 2023; operating margin approx. 33.3% (income from operations $57.6M / revenue $167.5M) in 2024 vs negative in 2023
- Best segment license revenue $167.5M in 2024 from Shionogi and others; worst segment research & development expenses $83.5M in 2024, up $9.6M YoY
- Cash $196.8M end 2024; Series D preferred stock sale raised $70.8M; IPO proceeds net $127.8M in Feb 2025; no debt drawn from $50M credit facility
- Management expects increasing R&D and G&A expenses; no commercial revenue forecasted; risk of financing shortfalls may delay operations or clinical programs
Risk Factors
- No geopolitical or macroeconomic threat detailed in the section
- Cybersecurity risk management led by Head of IT with 20+ years experience, ongoing monitoring and incident response program in place
- No competitive or market disruption risk mentioned in the section
- No financial or structural risk discussed in the section
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.